The reference implanted VNS device — an FDA-approved implanted VNS device (for drug-resistant epilepsy and treatment-resistant depression) with twenty-plus years of evidence — not equivalent to consumer devices.Reference medical device for understanding what non-invasive consumer VNS can and cannot replicate.
LivaNova VNS Therapy is the implanted vagus nerve stimulator that defined the modern VNS category. A pulse generator is surgically placed under the collarbone and wired to the left cervical vagus nerve; programming is done by a clinician. FDA-approved for drug-resistant epilepsy since 1997 and treatment-resistant depression since 2005. Included here as the medical reference point for understanding what non-invasive devices can and cannot replicate.
How we tested: Evidence-based assessment — scored from LivaNova clinical documentation, FDA-approved labelling and the published VNS Therapy registry literature. Included for context, as the implanted point of comparison, not as a consumer recommendation.
Twenty-plus years of FDA-approved use and hundreds of peer-reviewed studies. The pivotal trials were sponsored by the maker (Cyberonics, now LivaNova) and the registry data come from the maker, and studies run or funded by the maker do not count as evidence in ONDA scores; the independent literature alone still makes this the reference VNS evidence base.
Stimulation mechanism
9.5
Direct electrical stimulation of the cervical vagus nerve via surgically-implanted lead — the most direct stimulation possible. Programmable duty cycle, amplitude and frequency.
Protocol flexibility
8.5
Clinician-programmed continuous duty cycle plus closed-loop AutoStim (responsive to heart-rate changes in seizure prediction). Not user-adjustable by design.
Comfort and wearability
5.0
Surgical implant; post-operative scar and possible voice/throat side effects during stimulation. Lifetime device.
Procedure typically $25,000–30,000 plus implant; covered by insurance for cleared indications. Not a consumer purchase.
Pros
+An FDA-approved implanted VNS device (for drug-resistant epilepsy and treatment-resistant depression) with twenty-plus years of evidence — not equivalent to consumer devices
+Direct stimulation of the cervical vagus nerve — the most efficacious approach
+FDA-approved for drug-resistant epilepsy and treatment-resistant depression
−Restricted to clinically-indicated patients with prescribing specialist
−Voice change and throat discomfort during stimulation are common
−Procedure costs are insurance-mediated; not directly purchasable
Price: $27500 procedure + device; typically insurance-covered for indicated conditions (as of 2026-05-21)
Where it leads
LivaNova VNS Therapy is included in this list as the reference point — the implanted device that every non-invasive vagus stimulator is trying to approximate at one degree of indirection. A pulse generator the size of a small pocket watch is surgically placed under the left collarbone and wired to the cervical vagus nerve; the device fires on a clinician-programmed duty cycle and (in the SenTiva variant) closes the loop with on-device ECG-based seizure prediction. The evidence base is overwhelming: FDA-approved since 1997 for drug-resistant epilepsy and since 2005 for treatment-resistant depression, with hundreds of peer-reviewed studies; in the manufacturer's patient-outcome registry (5,554 patients), the share of responders rose from 49% in the first 4 months to 63% at 2–4 years, though only about 8% became seizure-free (Englot 2016).
What are the downsides of LivaNova VNS Therapy (SenTiva)?
It is a surgical implant. The patient pathway is a neurosurgeon, a hospital procedure, post-operative recovery, lifetime carriage of the device, and the well-documented intermittent side effects — voice change and throat discomfort during stimulation cycles. It is restricted to clinically-indicated patients with prescribing specialist sign-off, and costs are insurance-mediated rather than directly purchasable.
Who should buy LivaNova VNS Therapy (SenTiva)?
Not a consumer recommendation. LivaNova VNS Therapy is the gold-standard medical device for drug-resistant epilepsy and treatment-resistant depression — the right tool for the people meeting those criteria, prescribed by a specialist. For everyone else, non-invasive cervical (gammaCore, Truvaga) or auricular (Nurosym, Vagustim) devices approximate the mechanism without surgery, at known cost to the strength of the effect.
Background reading
The biology behind what these devices target — and the protocols that compound with the hardware.
LivaNova VNS Therapy (SenTiva) is a surgically implanted device that directly stimulates the cervical vagus nerve. It is FDA-approved for drug-resistant epilepsy and treatment-resistant depression, and is restricted to clinically indicated patients with a prescribing specialist. It is not a consumer device, and decisions about it belong with that specialist.
How much does LivaNova VNS Therapy cost?
The listed reference cost is around $27,500 for the procedure plus device, typically insurance-covered for indicated conditions. It cannot be bought directly: costs are insurance-mediated and access runs through a prescribing specialist, so the price a patient sees depends on their coverage rather than a retail price.
What are the downsides of LivaNova VNS Therapy?
The main downsides are that it is a surgical implant rather than a consumer device, it is limited to clinically indicated patients with a prescribing specialist, and voice change and throat discomfort during stimulation are common. Procedure costs are insurance-mediated, so it is not directly purchasable.
How does LivaNova VNS compare with consumer VNS devices?
LivaNova is an FDA-approved implanted VNS device (for drug-resistant epilepsy and treatment-resistant depression) with twenty-plus years of evidence — not equivalent to consumer devices — and uses direct cervical vagus stimulation, the most efficacious approach. The review treats it as a reference point for understanding what non-invasive consumer VNS devices can and cannot replicate, not as an alternative you choose off the shelf.
